Table 5. Overall response rate, efficacy subsets (part 2).
| |
|
Overall response rate |
Progression-free survival |
||
|---|---|---|---|---|---|
| Efficacy subsets | n | n (%) | 95% CI | Median (weeks) | 95% CI |
|
Hormone receptor status | |||||
| ER/PR+ | 55 | 46 (84) | 71.2–92.2 | 64.0 | 52.1–92.1 |
| ER/PR− |
44 |
26 (59) |
43.2–73.7 |
47.7 |
29.9–91.9 |
|
Prior therapy status | |||||
| First-line therapy | 33 | 23 (70) | 51.3–84.4 | 57.0 | 44.1–90.4 |
| Prior HER2-directed therapy | 38 | 27 (71) | 54.1–84.6 | 63.1 | 47.7–95.4 |
| Prior trastuzumab therapy | 28 | 20 (71) | 51.3–86.8 | 94.9 | 55.1–NE |
| Prior lapatinib therapy | 14 | 10 (71) | 41.9–91.6 | 44.3 | 23.4–64.0 |
| Prior endocrine therapy | 39 | 32 (82) | 66.5–92.5 | 52.1 | 39.7–81.4 |
| Prior taxane therapy | 62 | 50 (81) | 68.6–89.6 | 55.6 | 40.4–87.7 |
Abbreviations: CI=confidence interval; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; NE=not estimable; PR=progesterone receptor.